Serum p53 Antibodies in Patients Affected with Ulcerative Colitis
Open Access
- 1 September 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 10 (5) , 606-611
Abstract
During tumor progression, theaccumulation in genetic alterations is a fundamental characteristic of malignant cells. p53 gene is frequently mutated iKeywords
This publication has 32 references indexed in Scilit:
- Clinical Implication of Anti-p53 Antibodies and p53-Protein in Pancreatic DiseaseJournal of Gastrointestinal Cancer, 2002
- ABC of colorectal cancer: Molecular basis for risk factorsBMJ, 2000
- p27 Expression in Inflammatory Bowel Disease-Associated NeoplasiaThe American Journal of Pathology, 1999
- Evaluation of The Usefulness of Testing for P53 Mutations in Colorectal Cancer Surveillance for Ulcerative ColitisAmerican Journal of Gastroenterology, 1999
- Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancerJournal of Cancer Research and Clinical Oncology, 1996
- TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival materialBritish Journal of Cancer, 1996
- The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapyImmunology Today, 1996
- The relationship between serum p53 autoantibodies and characteristics of human breast cancerBritish Journal of Cancer, 1994
- p53 Point mutations in dysplastic and cancerous ulcerative colitis lesionsGastroenterology, 1993
- A genetic model for colorectal tumorigenesisCell, 1990